Antoni Esteve, Ph.D., is a member of the Board of Directors of Laboratorios del Dr. Esteve, S.A., (“Esteve”) one of Spain’s largest pharmaceutical and chemical manufacturing companies with operations in 40 countries and a presence in more than 60. Dr. Esteve was President of this company that bears his family name from 2005 – 2012. Dr. Esteve is also Chairman of the Blood and Tissue Bank (BST) owned by the Department of Health of the Government of Catalonia, and in 2009 he was appointed President of the Prince of Girona Foundation. He has also served as President of the National Association of the Pharmaceutical Industry in Spain as well as being a member of the Board of the European Federation of Pharmaceutical Industries and Associations. Dr. Esteve is also a member of the Royal Academies of Pharmacy and Medicine of Catalonia and a Permanent Member of the Royal Academy of Doctors of Spain. He holds a Doctorate in Pharmacy and PDD (Executive Development Program) from IESE (Business School of the University of Navarra, Barcelona, Spain).
Cosimo Pulli, Ph.D. serves as the senior executive responsible for Emerging Markets at Chiesi Farmaceutici SpA, one of Italy’s major pharmaceutical companies and the leader in R&D investment. Prior to being appointed head of Emerging Markets, Dr. Pulli served as Managing Director of Chiesi’s Pharmaceutical Division in Italy. His extensive experience has included time with Promedica SrL where he served as CEO, and Novadynamics SrL, where he was President, as well as having had a distinguished 15-year career with Glaxo. For many years, Dr. Pulli has been a Board Member of Farmindustria, the Italian association of pharmaceutical companies, and is currently a member of its Control Committee for the enforcement of the Code of Ethics. Dr. Pulli received his Doctoral degree from the University of Rome.
Massimo Bonsi, the Founder and CEO of the Solartium Group and Nutraceutics, based in Bucharest, Romania, has extensive international pharmaceutical industry experience. Dr. Bonsi’s significant experience spans both founding his own companies and in working with major pharmaceutical companies where he held senior management positions. He has particular pharmaceutical industry knowledge and expertise in the Eastern European region.
Anthony H. Wild, Ph.D., the former President of Warner-Lambert's Parke-Davis global Pharmaceutical business who earlier in his career was the president of Schering-Plough's Japanese operations. Currently, Dr. Wild is a member of the Board of Directors of Ranbaxy Laboratories and several privately-owned specialty pharmaceutical companies, including Innocoll, an international biopharmaceutical company, where he is Chairman of the Board of Directors. He also chairs the board of Sprout Pharmaceuticals and is on the board of advisors of Auven Therapeutics, a pharmaceutical venture fund. In 2001, Dr. Wild was a co-founder of MedPointe Pharmaceuticals Inc. where he was CEO until 2006, remaining as chairman until its acquisition by Meda AB of Sweden in 2007. Dr. Wild graduated in 1968 from the University of York where he earned an honors degree in Chemistry. He also holds a Ph.D. degree in physical chemistry from the University of Cambridge (Churchill College).
Rolf Smeets, Ph.D., is the Chief Medical Officer for Nutricia Advanced Medical Nutrition, a healthcare division of Danone. In this capacity, Dr. Smeets is a member of Nutricia’s Senior Management team, and has extensive experience and expertise in the areas of prescription Medical Foods, Foods for Special Medical Purposes, Functional Foods, and Nutritional Supplements. His responsibilities include the initiation and management of clinical trials, scientific, regulatory, and public affairs, as well as health economics and education. He also represents Nutricia Medical in its dealings with regulatory bodies in Europe and Asia as well as representing the company in the various Medical Nutrition Industry trade associations around the world. His prior career experience included R&D Program Director for Activia at Danone’s Research facilities in France, and prior to that he was Director of Medical Nutrition Research, at Danone Research in The Netherlands. Also, earlier in his career, Dr. Smeets was Director of New Product Development, GNC/Numico, based in Boca Raton, Florida, USA.
International Commercial Advisory Board
© Copyright by Prismic Pharmaceuticals, Inc.®, 2011-2019. All rights reserved.
Prismic Pharmaceuticals, Inc.
Attn: Zachary Dutton
474 Grove Street, Suite 740
Worcester, Massachusetts 01605